AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33851854 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening appointment costs
Number of subjects: 702
Study 33851854 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up/future treatment costs
Number of subjects: 702
Study 33851854 — intervention group
Group type: EXPERIMENTAL
Intervention: Lost pay due to time missed from work
Number of subjects: 702
Study 33851854 — intervention group
Group type: EXPERIMENTAL
Intervention: Transportation costs
Number of subjects: 702
Study 33851854 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived out-of-pocket cost of screening
Number of subjects: 702
Study 35365598 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib, cyclophosphamide, and dexamethasone (ICD)
Number of subjects: 112
Study 35365598 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide and dexamethasone (CD)
Number of subjects: 112
Study 34507244 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial combination therapy (fluoropyrimidine, bevacizumab, irinotecan)
Number of subjects: 421
Study 32093741 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactocare (ZistTakhmir) capsules 500 mg every 12 hours for 14 days
Number of subjects: 40
Study 32093741 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule containing only sterile maize starch, similar to synbiotic capsules for 14 days
Number of subjects: 40
Study 32619656 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic debridement alone (n=19)
Number of subjects: 36
Study 32619656 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic debridement with intraoperative PRP application (n=17)
Number of subjects: 36
Study 34181510 — intervention group
Group type: EXPERIMENTAL
Intervention: M18 (maize stored for 18 months)
Number of subjects: 270
Study 34181510 — intervention group
Group type: COMPARATOR
Intervention: M0 (maize stored for 24 days)
Number of subjects: 270
Study 34181510 — intervention group
Group type: EXPERIMENTAL
Intervention: M36 (maize stored for 36 months)
Number of subjects: 270
Study 34181510 — intervention group
Group type: EXPERIMENTAL
Intervention: M18
Number of subjects: 270
Study 34181510 — intervention group
Group type: EXPERIMENTAL
Intervention: M36
Number of subjects: 270
Study 34181510 — intervention group
Group type: EXPERIMENTAL
Intervention: M0 and M36
Number of subjects: 270
Study 34181510 — intervention group
Group type: COMPARATOR
Intervention: M0
Number of subjects: 270
Study 32316886 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment for insomnia (one group session of sleep hygiene education and four individual sessions of counseling)
Number of subjects: 44
Study 32316886 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 44
Study 32978842 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel antibiotic-free film-forming silicone-based wound dressing
Number of subjects: 231
Study 32978842 — intervention group
Group type: COMPARATOR
Intervention: Topical triple antibiotic petrolatum-based ointment
Number of subjects: 231
Study 33284129 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS text messaging and health education
Number of subjects: 420
Study 33284129 — intervention group
Group type: COMPARATOR
Intervention: Health education only (Control)
Number of subjects: 420
Study 33284129 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Intervention and Control)
Number of subjects: 420
Study 35069809 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable transcutaneous electrical nerve stimulation (W‐TENS)
Number of subjects: 110
Study 35069809 — intervention group
Group type: COMPARATOR
Intervention: Weak opioids (WO)
Number of subjects: 110
Study 33357512 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole (50 mg twice a day for 14 days before surgery and then for 28 days after surgery)
Number of subjects: 290
Study 33357512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study 33357512 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole
Number of subjects: 290
Study 35030242 — intervention group
Group type: EXPERIMENTAL
Intervention: Active implicit priming (IP)
Number of subjects: 41
Study 35030242 — intervention group
Group type: COMPARATOR
Intervention: Control implicit priming (IP)
Number of subjects: 41
Study 33971855 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified guidance (3-page version)
Number of subjects: 1845
Study 33971855 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified guidance with visual aids (3-page version with pictograms)
Number of subjects: 1845
Study 33971855 — intervention group
Group type: COMPARATOR
Intervention: Control (7-page standard guidelines)
Number of subjects: 1845
Study 35321888 — intervention group
Group type: COMPARATOR
Intervention: Completion surgery followed by an additional five cycles of chemotherapy (control arm)
Number of subjects: 210
Study 35321888 — intervention group
Group type: EXPERIMENTAL
Intervention: An additional three cycles of neoadjuvant chemotherapy followed by completion surgery and then two additional cycles of chemotherapy (experimental arm)
Number of subjects: 210
Study 33683608 — intervention group
Group type: EXPERIMENTAL
Intervention: Humanoid robot-based distraction
Number of subjects: 86
Study 33683608 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 86
Study 32927371 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure treatment
Number of subjects: 31
Study 32927371 — intervention group
Group type: COMPARATOR
Intervention: Non-exposure based treatment
Number of subjects: 31
Study 35769481 — intervention group
Group type: EXPERIMENTAL
Intervention: WASH intervention (n = 33)
Number of subjects: 113
Study 35769481 — intervention group
Group type: EXPERIMENTAL
Intervention: Stunted children (n = 44)
Number of subjects: 113
Study 35769481 — intervention group
Group type: COMPARATOR
Intervention: IYCF (n = 55)
Number of subjects: 113
Study 33657450 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI treatment (10mg escitalopram)
Number of subjects: 66
Study 33657450 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 66
Study 35905798 — intervention group
Group type: EXPERIMENTAL
Intervention: Baduanjin (BDJ) exercise for 24 weeks
Number of subjects: 80
Study 35905798 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga exercise for 24 weeks
Number of subjects: 80
Study 35905798 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual activity)
Number of subjects: 80
Study 34510501 — intervention group
Group type: EXPERIMENTAL
Intervention: Average Treatment Effect (ATE)
Number of subjects: 0
Study 34510501 — intervention group
Group type: EXPERIMENTAL
Intervention: Average Treated Effect in the Treated (ATT)
Number of subjects: 0
Study 34510501 — intervention group
Group type: EXPERIMENTAL
Intervention: Overlap Weights
Number of subjects: 0
Study 34510501 — intervention group
Group type: EXPERIMENTAL
Intervention: Matching Weights
Number of subjects: 0
Study 34510501 — intervention group
Group type: EXPERIMENTAL
Intervention: Entropy Weights
Number of subjects: 0
Study 33167109 — intervention group
Group type: EXPERIMENTAL
Intervention: rSO2 guides controlled hypotension (group A)
Number of subjects: 120
Study 35720011 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS)
Number of subjects: 91
Study 35720011 — intervention group
Group type: COMPARATOR
Intervention: Control group (transcutaneous electrical stimulation at nonacupoint position)
Number of subjects: 91
Study 35367733 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow derived stem cells (BMSCs)
Number of subjects: 27
Study 35367733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 34190947 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic communication application (IG group, n=30)
Number of subjects: 60
Study 34190947 — intervention group
Group type: COMPARATOR
Intervention: Traditional class (CG group, n=30)
Number of subjects: 60
Study 32938496 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab + methylprednisolone plus standard of care (SOC) for COVID-19
Number of subjects: 200
Study 32938496 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone plus standard of care (SOC) for COVID-19
Number of subjects: 200
Study 34227392 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI with drug-eluting stents
Number of subjects: 600
Study 34227392 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 600
Study 33075612 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Deprivation (SD)
Number of subjects: 19229
Study 33075612 — intervention group
Group type: EXPERIMENTAL
Intervention: Habitual Sleep Deprivation
Number of subjects: 19229
Study 33075612 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekday Sleep Deprivation
Number of subjects: 19229
Study 33075612 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekend Sleep Deprivation
Number of subjects: 19229
Study 33075612 — intervention group
Group type: COMPARATOR
Intervention: Sleepwalking
Number of subjects: 19229
Study 36398978 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach-oriented coping
Number of subjects: 170
Study 36398978 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidant coping
Number of subjects: 170
Study 32536331 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg lorazepam
Number of subjects: 26
Study 32536331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 35151504 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (1 mg)
Number of subjects: 964
Study 35151504 — intervention group
Group type: COMPARATOR
Intervention: Bupropion (150 mg)
Number of subjects: 964
Study 34278042 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day orally for 90 days
Number of subjects: 168
Study 34278042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 35076090 — intervention group
Group type: EXPERIMENTAL
Intervention: galcanezumab 120 mg
Number of subjects: 2680
Study 35076090 — intervention group
Group type: EXPERIMENTAL
Intervention: galcanezumab 240 mg
Number of subjects: 2680
Study 35076090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2680
Study 33601121 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (2000 IU/d)
Number of subjects: 753
Study 33601121 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (400 IU/d)
Number of subjects: 753
Study 33601121 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Vitamin A (2000 IU/d) and Vitamin D (400 IU/d)
Number of subjects: 753
Study 33601121 — intervention group
Group type: COMPARATOR
Intervention: Control group (tuberculosis treatment only)
Number of subjects: 753
Study 33356728 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix (Strattice™)
Number of subjects: 29
Study 33356728 — intervention group
Group type: COMPARATOR
Intervention: Synthetic mesh (Prolene®)
Number of subjects: 29
Study 36242723 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive outpatient care based on Comprehensive Geriatric Assessment
Number of subjects: 1212
Study 36242723 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1212
Study 34755627 — intervention group
Group type: EXPERIMENTAL
Intervention: Maralixibat 380 μg/kg once per day for 18 weeks, followed by random assignment to continue maralixibat or receive placebo for 4 weeks.
Number of subjects: 31
Study 34755627 — intervention group
Group type: EXPERIMENTAL
Intervention: Maralixibat continued treatment
Number of subjects: 31
Study 34755627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 34755627 — intervention group
Group type: EXPERIMENTAL
Intervention: Maralixibat continued treatment until week 204
Number of subjects: 31
Study 34622766 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine group
Number of subjects: 119110
Study 34622766 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 119110
Study 33483613 — intervention group
Group type: EXPERIMENTAL
Intervention: IM 400 mg
Number of subjects: 787
Study 33483613 — intervention group
Group type: EXPERIMENTAL
Intervention: IM 600 mg
Number of subjects: 787
Study 33483613 — intervention group
Group type: EXPERIMENTAL
Intervention: IM 400 mg + cytarabine (AraC)
Number of subjects: 787
Study 33483613 — intervention group
Group type: EXPERIMENTAL
Intervention: IM 400 mg + pegylated interferon alpha2a (PegIFN‐α2a)
Number of subjects: 787
Study 33618023 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab every 8 weeks
Number of subjects: 0
Study 33618023 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab every 12 weeks
Number of subjects: 0
Study 33618023 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (LTE)
Number of subjects: 0
Study 33618023 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab
Number of subjects: 0
Study 33618023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33640516 — intervention group
Group type: EXPERIMENTAL
Intervention: SRAE with 500-700 μm tris-acryl gelatin microspheres
Number of subjects: 42
Study 33640516 — intervention group
Group type: EXPERIMENTAL
Intervention: SRAE with 700-900 μm tris-acryl gelatin microspheres
Number of subjects: 42
Study 33640516 — intervention group
Group type: EXPERIMENTAL
Intervention: SRAE with 900-1,200 μm tris-acryl gelatin microspheres
Number of subjects: 42
Study 33640516 — intervention group
Group type: EXPERIMENTAL
Intervention: SRAE with tris-acryl gelatin microspheres (all groups)
Number of subjects: 42
Study 35472008 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole (40 mg twice daily)
Number of subjects: 30
Study 35472008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 33487305 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect calorimetry with FFP2 mask
Number of subjects: 10
Study 33487305 — intervention group
Group type: COMPARATOR
Intervention: Indirect calorimetry without FFP2 mask
Number of subjects: 10
Study 36002798 — intervention group
Group type: EXPERIMENTAL
Intervention: BF text messages plus app
Number of subjects: 346
Study 36002798 — intervention group
Group type: EXPERIMENTAL
Intervention: BF text messages, app and physician-moderated private Facebook group
Number of subjects: 346
Study 36002798 — intervention group
Group type: COMPARATOR
Intervention: Attention control group (injury prevention texts)
Number of subjects: 346
Study 34494323 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g soy flour (whole soy group)
Number of subjects: 270
Study 34494323 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g low-fat milk powder + 63 mg daidzein (daidzein group)
Number of subjects: 270
Study 34494323 — intervention group
Group type: COMPARATOR
Intervention: 40 g low-fat milk powder (placebo)
Number of subjects: 270
Study 35468621 — intervention group
Group type: EXPERIMENTAL
Intervention: F16IL2 (10 × 10^6 to 20 × 10^6 IU IV; days 1, 8, 15, and 22 of each 28‐day cycle) + BI 836858 (10-40 mg IV, 2 days after each F16IL2 infusion)
Number of subjects: 15
Study 35468621 — intervention group
Group type: EXPERIMENTAL
Intervention: F16IL2 + BI 836858
Number of subjects: 15
Study 32071262 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher short sleep duration score
Number of subjects: 107
Study 32071262 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher late sleep score
Number of subjects: 107
Study 32071262 — intervention group
Group type: EXPERIMENTAL
Intervention: Habitual late sleep in high risk children
Number of subjects: 107
Study 35283262 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory drug for heart failure
Number of subjects: 100
Study 35283262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 33576005 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to scented products (leave-on products and specific scented product subgroups)
Number of subjects: 3119
Study 33576005 — intervention group
Group type: EXPERIMENTAL
Intervention: Female participants
Number of subjects: 3119
Study 33576005 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants age 40 years and older
Number of subjects: 3119
Study 33576005 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitive skin
Number of subjects: 3119
Study 33576005 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggregate exposure to scented leave-on products
Number of subjects: 3119
Study 36036611 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-Lumefantrine (AL)
Number of subjects: 340
Study 36036611 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-Piperaquine (DP)
Number of subjects: 340
Study 34936264 — intervention group
Group type: EXPERIMENTAL
Intervention: Nape cluster acupuncture
Number of subjects: 120
Study 34378458 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable defibrillators
Number of subjects: 2521
Study 34378458 — intervention group
Group type: EXPERIMENTAL
Intervention: Sigmoidal model
Number of subjects: 2521
Study 34378458 — intervention group
Group type: COMPARATOR
Intervention: Linear model
Number of subjects: 2521
Study 33450736 — intervention group
Group type: EXPERIMENTAL
Intervention: SAFIRE grade I
Number of subjects: 405
Study 33450736 — intervention group
Group type: EXPERIMENTAL
Intervention: SAFIRE grade II
Number of subjects: 405
Study 33450736 — intervention group
Group type: EXPERIMENTAL
Intervention: SAFIRE grade III
Number of subjects: 405
Study 33450736 — intervention group
Group type: EXPERIMENTAL
Intervention: SAFIRE grade IV
Number of subjects: 405
Study 33450736 — intervention group
Group type: EXPERIMENTAL
Intervention: SAFIRE grade V
Number of subjects: 405
Study 33450736 — intervention group
Group type: EXPERIMENTAL
Intervention: SAFIRE grade IV or V
Number of subjects: 405
Study 34879326 — intervention group
Group type: EXPERIMENTAL
Intervention: %TTD macro program
Number of subjects: 0
Study 34879326 — intervention group
Group type: EXPERIMENTAL
Intervention: %TUDD macro program
Number of subjects: 0
Study 32072866 — intervention group
Group type: EXPERIMENTAL
Intervention: FamTechCare video support
Number of subjects: 84
Study 32072866 — intervention group
Group type: COMPARATOR
Intervention: Telephone support (control)
Number of subjects: 84
Study 34952574 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D printing personalized percutaneous puncture guide access plate for PCNL
Number of subjects: 22
Study 34952574 — intervention group
Group type: COMPARATOR
Intervention: Standard USG guide PCNL
Number of subjects: 22
Study 32614264 — intervention group
Group type: EXPERIMENTAL
Intervention: OSG+V (online synchronous chat group with AYA-created film)
Number of subjects: 34
Study 32614264 — intervention group
Group type: COMPARATOR
Intervention: OSG+E (online synchronous chat group plus education)
Number of subjects: 34
Study 34327538 — intervention group
Group type: EXPERIMENTAL
Intervention: NIO automatic intraosseous device
Number of subjects: 60
Study 34327538 — intervention group
Group type: COMPARATOR
Intervention: TALON manual intraosseous device
Number of subjects: 60
Study 34658904 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality (VR) during exercise test
Number of subjects: 70
Study 34658904 — intervention group
Group type: COMPARATOR
Intervention: Standard exercise test (without VR)
Number of subjects: 70
Study 35552107 — intervention group
Group type: COMPARATOR
Intervention: WT+RUPP
Number of subjects: 24
Study 35552107 — intervention group
Group type: EXPERIMENTAL
Intervention: KO+RUPP
Number of subjects: 24
Study 32347934 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 150 mg (3 days/week) with TMZ 75 mg/m2 daily for 42 days
Number of subjects: 39
Study 32347934 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 39
Study 36227220 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored nutritional dietary rehabilitation plan including dietary supplements
Number of subjects: 100
Study 36227220 — intervention group
Group type: COMPARATOR
Intervention: Dietary advice only
Number of subjects: 100
Study 34916320 — intervention group
Group type: COMPARATOR
Intervention: Conventional regimen of doxorubicin and cisplatin
Number of subjects: 377
Study 34916320 — intervention group
Group type: COMPARATOR
Intervention: Dose-intense regimen of doxorubicin and cisplatin
Number of subjects: 377
Study 34711482 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid palatal expansion (RPE) using hyrax-type appliances
Number of subjects: 80
Study 34711482 — intervention group
Group type: COMPARATOR
Intervention: Nontreated control group
Number of subjects: 80
Study 34711482 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid palatal expansion (RPE)
Number of subjects: 80
Study 32865258 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) programme
Number of subjects: 58
Study 32865258 — intervention group
Group type: COMPARATOR
Intervention: Theoretical training session
Number of subjects: 58
Study 36327399 — intervention group
Group type: EXPERIMENTAL
Intervention: Salicylic acid via foliar spraying
Number of subjects: 5
Study 36327399 — intervention group
Group type: EXPERIMENTAL
Intervention: Salicylic acid via irrigation
Number of subjects: 5
Study 36327399 — intervention group
Group type: COMPARATOR
Intervention: Control (without application of salicylic acid)
Number of subjects: 5
Study 36327399 — intervention group
Group type: EXPERIMENTAL
Intervention: Salicylic acid via spraying and irrigation
Number of subjects: 5
Study 36327399 — intervention group
Group type: EXPERIMENTAL
Intervention: Salicylic acid via spraying
Number of subjects: 5
Study 32851713 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous nephrostomy
Number of subjects: 143
Study 32851713 — intervention group
Group type: COMPARATOR
Intervention: JJ stent
Number of subjects: 143
Study 32851713 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 143
Study 35389367 — intervention group
Group type: EXPERIMENTAL
Intervention: CareHand app (tailored exercise program, self-management and monitoring tools)
Number of subjects: 36
Study 35389367 — intervention group
Group type: EXPERIMENTAL
Intervention: CareHand app
Number of subjects: 36
Study 35389367 — intervention group
Group type: COMPARATOR
Intervention: Usual care (written home exercise routine and recommendations)
Number of subjects: 36
Study 34210333 — intervention group
Group type: EXPERIMENTAL
Intervention: Feel4Diabetes-intervention (2-year multilevel intervention including counseling sessions and text messages)
Number of subjects: 4484
Study 34210333 — intervention group
Group type: EXPERIMENTAL
Intervention: Feel4Diabetes-intervention
Number of subjects: 4484